a Department of Medicine , Kuopio University Hospital , Kuopio , Finland.
b Department of Medicine , Kymenlaakso Central Hospital , Kotka , Finland.
Expert Rev Hematol. 2016 Aug;9(8):723-32. doi: 10.1080/17474086.2016.1208082. Epub 2016 Jul 15.
A combination of granulocyte colony-stimulating factor (G-CSF) and chemotherapy or G-CSF alone are the most common mobilization regimens for autotransplantations. Plerixafor is used for mobilization of CD34(+) cells with G-CSF in non-Hodgkin lymphoma (NHL) and myeloma (MM) patients.
The available phase II and III data on plerixafor has been reviewed. The efficacy of plerixafor in the mobilization of CD34(+) cells in predicted poor mobilizers as well as in patients who had failed a mobilization has been evaluated. The pre-emptive use of plerixafor as well as studies on cost-effectiveness are covered. Also effects in the composition of the collected grafts along with the data on long-term outcome of plerixafor-mobilized patients is discussed. Expert commentary: Plerixafor combined with G-CSF mobilizes CD34(+) cells more efficiently than G-CSF alone in patients with NHL or MM. In phase III studies, engraftment after high-dose therapy has been comparable to G-CSF mobilized patients. The pre-emptive use of plerixafor added to mobilization with chemotherapy plus G-CSF or with G-CSF alone has gained more popularity. This approach may be more cost-effective than the routine use of this drug. The changes observed in the composition of grafts after plerixafor injection may have implications for post-transplant events.
集落刺激因子（G-CSF）联合化疗或 G-CSF 单药是自体移植最常用的动员方案。培洛昔芬与 G-CSF 联合用于非霍奇金淋巴瘤（NHL）和骨髓瘤（MM）患者的 CD34+细胞动员。
综述了培洛昔芬的现有 II 期和 III 期数据。评估了培洛昔芬在预测动员不良患者和动员失败患者中动员 CD34+细胞的疗效。还涵盖了培洛昔芬的抢先使用以及成本效益研究。同时还讨论了采集移植物成分的变化以及培洛昔芬动员患者的长期结果数据。
培洛昔芬联合 G-CSF 比 NHL 或 MM 患者单用 G-CSF 更有效地动员 CD34+细胞。在 III 期研究中，高剂量治疗后的植入与 G-CSF 动员患者相当。培洛昔芬与化疗联合 G-CSF 或 G-CSF 联合动员的抢先使用更受欢迎。这种方法可能比常规使用这种药物更具成本效益。培洛昔芬注射后移植物成分观察到的变化可能对移植后事件有影响。
